Searchable abstracts of presentations at key conferences in endocrinology

ea0026p242 | Pituitary | ECE2011

Relationship between GH activity and markers of inflammation: a cross-over study of healthy volunteers treated with GH and a GH antagonist for 3 weeks

Andreassen M , Frystyk J , Faber J , Kristensen L O

Introduction: Observations in patients with GH disturbances and in normal populations have suggested that GH/IGF1 activity could have anti-inflammatory effects. On the other hand, in vitro studies have shown that IGF1 may stimulate the immune system.Methods/design: The study population consisted of 12 healthy volunteers (mean age 36, range 27–49 years) treated with GH for 3 weeks (1st week 0.01 mg/day, 2nd 0.02 mg/day, 3rd 0.03 mg/day) and su...

ea0035p671 | Growth hormone IGF axis basic | ECE2014

Epigenetic regulation of GH target genes and its relation to in vivo GH signaling in skeletal muscle of adult human males: a pilot study

Pedersen Morten H , Vestergaard Poul F , Switnicki Michal , Jessen Niels , Jorgensen Jens O L

Background: GH secretion and action change with age in adult human subjects, and this play an important role in substrate metabolism in aging subjects. Targeted disruption of the GH receptor in mice extends longevity, and this is associated with decreased expression of apoptosis-related genes including caspase-9 (CASP9) in skeletal muscle.Aim: To study DNA methylation of putative GH target genes in skeletal muscle of adult male subjects in relation to bo...

ea0011p609 | Neuroendocrinology and behaviour | ECE2006

Effect of pegvisomant on glucose metabolism

Aznar S , Boix E , Revert P , Moreno O , López-Maciá A , Picó A

Aim: To quantify the effect of pegvisomant on glucose homeostasis, lipid profile and disease activity in acromegaly.Methods: 5 Patients with active acromegaly after surgery, radiotherapy and somatostatin analogs were included. Somatostatin analogs were withdrawn 6 weeks before starting pegvisomant and it was initially administered subcutaneously at doses of 10 mg daily. Doses were progressively increased every 3 to 4 weeks until IGF1 normalization. Gluco...

ea0065p276 | Neuroendocrinology | SFEBES2019

The effect of tumor staining pattern on secondary hormonal deficiency in nonfunctioning pituitary adenomas

Ali Imran Syed , Almistehi Wael M , Hebb Andrea L O , Doucette Steve , Tramble Lisa , Massoud Emad , Clarke David B

Secondary hormonal deficiency (SHD) is common in patients presenting with nonfunctioning pituitary adenomas (NFA). NFA can either stain for various hormones or be non-hormone staining on immunocytochemistry. To date, no study has assessed the association between staining pattern of NFA and pattern of SHD at presentation. The Halifax Neuropituitary Program has been prospectively collecting comprehensive data on all neuropituitary patients in the province of Nova Scotia, Canada ...

ea0026p268 | Pituitary | ECE2011

Frequency of acute-onset symptoms and other features of craniopharyngioma presentation in children and adults

Nielsen E H , Jorgensen J O , Bjerre P , Andersen M , Andersen C , Feldt-Rasmussen U , Poulsgaard L , Kristensen L O , Astrup Jens , Lindholm Jorgen , Laurberg Peter

Introduction: Clinical symptoms in craniopharyngioma have been repeatedly described in the literature, but few studies have addressed the issue of acute-onset symptoms in children or adults. Refinements of diagnostic procedures and altered scanning routines over the last two decades may in theory have affected patterns of clinical presentation.Objective: To study the clinical phenotype of patients with newly diagnosed craniopharyngioma, with focus on var...